Clinuvel Pharmaceuticals Past Earnings Performance
Past criteria checks 4/6
Clinuvel Pharmaceuticals has been growing earnings at an average annual rate of 15.8%, while the Biotechs industry saw earnings growing at 12.6% annually. Revenues have been growing at an average rate of 22.9% per year. Clinuvel Pharmaceuticals's return on equity is 17.6%, and it has net margins of 40.4%.
Key information
15.8%
Earnings growth rate
15.4%
EPS growth rate
| Biotechs Industry Growth | 9.6% |
| Revenue growth rate | 22.9% |
| Return on equity | 17.6% |
| Net Margin | 40.4% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
If EPS Growth Is Important To You, Clinuvel Pharmaceuticals (ASX:CUV) Presents An Opportunity
Aug 11
Calculating The Intrinsic Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)
Jun 27Is Now The Time To Put Clinuvel Pharmaceuticals (ASX:CUV) On Your Watchlist?
May 09Estimating The Intrinsic Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)
Mar 24An Intrinsic Calculation For Clinuvel Pharmaceuticals Limited (ASX:CUV) Suggests It's 41% Undervalued
Nov 18Increases to Clinuvel Pharmaceuticals Limited's (ASX:CUV) CEO Compensation Might Cool off for now
Oct 20Is Clinuvel Pharmaceuticals Limited (ASX:CUV) Trading At A 21% Discount?
Jul 30Clinuvel Pharmaceuticals Limited (ASX:CUV) Shares Could Be 27% Below Their Intrinsic Value Estimate
Feb 27Does Clinuvel Pharmaceuticals (ASX:CUV) Deserve A Spot On Your Watchlist?
Dec 14This Is The Reason Why We Think Clinuvel Pharmaceuticals Limited's (ASX:CUV) CEO Might Be Underpaid
Nov 03A Look At The Fair Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)
Sep 23Here's Why I Think Clinuvel Pharmaceuticals (ASX:CUV) Might Deserve Your Attention Today
Jul 23With EPS Growth And More, Clinuvel Pharmaceuticals (ASX:CUV) Is Interesting
Apr 10Have Insiders Sold Clinuvel Pharmaceuticals Limited (ASX:CUV) Shares Recently?
Mar 06Earnings Miss: Clinuvel Pharmaceuticals Limited Missed EPS By 41% And Analysts Are Revising Their Forecasts
Feb 27What Is The Ownership Structure Like For Clinuvel Pharmaceuticals Limited (ASX:CUV)?
Feb 20Clinuvel Pharmaceuticals (ASX:CUV) Shareholders Have Enjoyed A Whopping 648% Share Price Gain
Feb 01Estimating The Fair Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)
Jan 14We Wouldn't Rely On Clinuvel Pharmaceuticals's (ASX:CUV) Statutory Earnings As A Guide
Dec 28
Clinuvel Pharmaceuticals Limited's (ASX:CUV) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Dec 10What You Need To Know About Clinuvel Pharmaceuticals Limited's (ASX:CUV) Investor Composition
Nov 21Revenue & Expenses Breakdown
How Clinuvel Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 88 | 36 | 29 | 2 |
| 31 Mar 24 | 85 | 33 | 29 | 2 |
| 31 Dec 23 | 82 | 30 | 29 | 1 |
| 30 Sep 23 | 80 | 30 | 27 | 1 |
| 30 Jun 23 | 78 | 31 | 25 | 1 |
| 31 Mar 23 | 74 | 29 | 23 | 1 |
| 31 Dec 22 | 70 | 26 | 21 | 1 |
| 30 Sep 22 | 68 | 24 | 20 | 1 |
| 30 Jun 22 | 66 | 21 | 19 | 1 |
| 31 Mar 22 | 62 | 22 | 18 | 1 |
| 31 Dec 21 | 57 | 24 | 17 | 1 |
| 30 Sep 21 | 53 | 24 | 16 | 1 |
| 30 Jun 21 | 48 | 25 | 14 | 1 |
| 31 Mar 21 | 43 | 23 | 14 | -1 |
| 31 Dec 20 | 38 | 21 | 14 | -3 |
| 30 Sep 20 | 35 | 18 | 13 | -1 |
| 30 Jun 20 | 33 | 15 | 12 | 0 |
| 31 Mar 20 | 32 | 15 | 10 | 4 |
| 31 Dec 19 | 32 | 15 | 8 | 8 |
| 30 Sep 19 | 32 | 16 | 7 | 7 |
| 30 Jun 19 | 31 | 18 | 6 | 7 |
| 31 Mar 19 | 29 | 17 | 6 | 7 |
| 31 Dec 18 | 27 | 16 | 6 | 6 |
| 30 Sep 18 | 26 | 15 | 6 | 6 |
| 30 Jun 18 | 25 | 13 | 6 | 6 |
| 31 Mar 18 | 21 | 10 | 6 | 5 |
| 31 Dec 17 | 17 | 6 | 6 | 5 |
| 30 Sep 17 | 17 | 7 | 6 | 4 |
| 30 Jun 17 | 17 | 7 | 5 | 4 |
| 31 Mar 17 | 14 | 5 | 5 | 4 |
| 31 Dec 16 | 12 | 3 | 4 | 4 |
| 30 Sep 16 | 9 | 0 | 4 | 4 |
| 30 Jun 16 | 7 | -3 | 5 | 4 |
| 31 Mar 16 | 5 | -5 | 3 | 3 |
| 31 Dec 15 | 4 | -6 | 2 | 3 |
| 30 Sep 15 | 4 | -8 | 4 | 3 |
| 30 Jun 15 | 3 | -10 | 6 | 3 |
| 31 Mar 15 | 3 | -10 | 8 | 3 |
| 31 Dec 14 | 3 | -10 | 9 | 3 |
| 30 Sep 14 | 3 | -8 | 7 | 3 |
| 30 Jun 14 | 3 | -6 | 5 | 3 |
| 31 Mar 14 | 3 | -6 | 5 | 3 |
| 31 Dec 13 | 2 | -6 | 5 | 3 |
Quality Earnings: CUV has a high level of non-cash earnings.
Growing Profit Margin: CUV's current net profit margins (40.4%) are higher than last year (39.1%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CUV's earnings have grown by 15.8% per year over the past 5 years.
Accelerating Growth: CUV's earnings growth over the past year (16.4%) exceeds its 5-year average (15.8% per year).
Earnings vs Industry: CUV earnings growth over the past year (16.4%) exceeded the Biotechs industry 2.6%.
Return on Equity
High ROE: CUV's Return on Equity (17.6%) is considered low.